Entecavir‐induced neutropenia in an adult living donor liver transplant recipient: Successful conversion to tenofovir alafenamide

Abstract

Key Clinical Message At 22 weeks post‐transplantation for HBV‐related cirrhosis, an adult woman developed neutropenia which was aggravated by COVID‐19 (ANC 0.4 × 109/L). Covid resolution and all “conventional” modifications were ineffective. Success within 2 weeks was achieved by switching entecavir to tenofovir alafenamide. A step‐by‐step judicious approach to post‐transplant neutropenia is vital.

Keywords

• COVID‐19
• entecavir
• liver transplantation
• neutropenia
• tenofovir alafenamide